<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494585</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0070</org_study_id>
    <secondary_id>CS-2007-20040</secondary_id>
    <nct_id>NCT00494585</nct_id>
  </id_info>
  <brief_title>CEP-701 for PH-negative Myelofibrosis</brief_title>
  <official_title>Evaluation of CEP-701, an Orally Available JAK2 Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find out if CEP-701 can help control
      myelofibrosis (MF). The safety of CEP-701 will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drug:

      CEP-701 is designed to help prevent a certain type of molecule (called a mutated JAK2
      receptor) that is found on myelofibrosis cells from sending continuous chemical signals that
      lead to the growth of cancer cells.

      Study Treatment:

      If you are found to be eligible to take part in this study, you will take CEP-701 by mouth
      (in liquid form) 2 times a day (once in the morning and once in the evening) every day in
      30-day repeating cycles. You should take each dose about 12 hours apart.

      The study doctor or nurse will teach you and/or a caregiver or family member how to prepare
      each dose of the study drug, as well as how much should be taken each time. At each study
      visit, you will be supplied with enough syringes, dosing cups, and study drug to last until
      your next study visit. For each dose, you will use the syringe to draw the proper amount of
      CEP-701. You will add the entire contents of the syringe to an approved juice in 1 of the
      provided dosing cups. You should also drink an additional dosing cup of juice after taking
      the drug dose. The following juices (100% juice only) are approved for use with CEP-701:
      grape, pineapple, apple, V8 vegetable juice, and orange juice.

      The study drug mixture may be stored (in an areas that are protected from light, such as in a
      cabinet) for up to 1 hour at room temperature and up to 8 hours refrigerated (at about 35°F
      to 45 °F). If you miss a dose, you should not take another dose until your next scheduled
      dose.

      Study Visits:

      You will initially have study visits at M. D. Anderson once a month. You will need to return
      monthly for 6 months, then every 3 months if there are no side effects during the previous 3
      cycles. After 2 years of therapy, your visits can be extended to every 6 months. After 6
      cycles you may have either a study visit or a phone call from a member of study staff. If you
      have a phone call, you will be asked how you are feeling, if you have experienced any side
      effects since your last visit, and your blood tests will be reviewed with you. During most
      study visits, you will have the following tests:

        -  You will have a physical exam.

        -  You will be asked how you are feeling and about any side effects you may have
           experienced since your last visit.

        -  You will have blood (about 2 tablespoons) drawn to check your kidney and liver function
           and blood cell count. This will be done every 2 weeks up to 3 months, then every 1-2
           months.

        -  You will have a bone marrow/aspirate once every 3-6 months to see if you are responding
           to treatment. After 2 years of therapy, this can be extended to every 12 months.

      Length of Study:

      You will continue on this study for at least 6 months to allow time for response. If you do
      respond to study treatment, you may continue to receive cycles for up to 5 years.

      If you do not respond to study treatment within 6 months, if the disease gets worse, if
      intolerable side effects occur, if you have an illness that keeps you from taking the study
      drug, or your doctor thinks it is in your best interest to stop taking part in this study,
      you will be taken off this study.

      This is an investigational study. CEP-701 is not Food and Drug Administration (FDA) approved
      or commercially available. At this time, it is being used for research purposes only in this
      study. Up to 41 patients will take part in this study. All will be enrolled at M. D.
      Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Objective Response</measure>
    <time_frame>Response assessed after each 3 cycles (cycle = 30 days)</time_frame>
    <description>Objective response = Complete Response, absence sign/symptoms of disease (without use of growth factors, hydroxyurea, anagrelide, or transfusions for &gt; 1 month); Partial Response, absence of progressive disease (PD), and improvement in 2+ parameters (if abnormal): Absolute neutrophil count (ANC), hemoglobin, platelets, transfusions, splenomegaly, or bone marrow blasts; Clinical Improvement, absence of PD, and improvement in 1 parameter: ANC, hemoglobin, platelets, transfusions, splenomegaly, or bone marrow blasts). [International Working Group on Myelofibrosis Research and Treatment]</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>CEP-701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg orally twice a day for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEP-701</intervention_name>
    <description>80 mg orally twice a day for 30 days</description>
    <arm_group_label>CEP-701</arm_group_label>
    <other_name>lestaurtinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Chronic Idiopathic Myelofibrosis (CIMF) requiring therapy, including
             those 1) previously treated by CIMF-directed therapy and relapsed, intolerant, or
             refractory to therapy; or 2) if newly diagnosed then with intermediate or high risk
             according to Lille scoring system (adverse prognostic factors are: Hb &lt; 10 g/dl, WBC &lt;
             4 or &gt; 30 x 10^9/L; risk group: 0 = low, 1 = intermediate, 2 = high), or with
             symptomatic spleen that is &gt;/= 10cm below costal margin. However, patients with
             asymptomatic intermediate risk disease are not eligible.

          -  JAK2 mutation positive test

          -  Age of at least 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Adequate liver and renal function: total bilirubin &lt;/=2.0 mg/dL, alanine
             aminotransferase (ALT or SGPT) &lt;/=2.0 x institutional upper limit of normal (ULN), and
             creatinine &lt;/=2.0 mg/dl

          -  Patients must be at least 2 weeks from prior chemotherapy, biological therapy,
             radiation therapy, major surgery, or other investigational anticancer therapy that is
             considered MF-directed, and have recovered from prior toxicities to Grade 0-1.
             Concurrent therapy with supportive care medications (hydroxyurea, anagrelide) is
             allowed during the study.

          -  All men of reproductive potential and women of child-bearing potential (WOCBP) must
             agree to practice effective contraception (iud, birth control pill, latex condoms,
             diaphragm) during the entire study period and for one month after the study ends,
             unless documentation of infertility exists. Should a woman become pregnant or suspect
             she is pregnant while participating in this study, she should inform her treating
             physician immediately. WOCBP are women who are not menopausal for 12 months or no
             previous surgical sterilization.&quot;

          -  Ability to understand and willingness to sign the informed consent form

          -  Not willing to undergo, not a candidate for, or not having a donor for, a bone marrow
             transplant

        Exclusion Criteria:

          -  Pregnant or nursing women, due to the unknown effects of therapy on the developing
             fetus or newborn infant.

          -  Patients diagnosed with another malignancy - unless following curative intent therapy
             the patient has been disease free for at least 3 years. Patients with early stage
             squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical
             intraepithelial neoplasia (CIN) are eligible for this study

          -  Any condition, including serious medical condition, laboratory abnormality, or
             psychiatric illness, which places the subject at unacceptable risk as judged by the
             Principal Investigator, if he/she was to participate in the study

          -  Known positive for Human immunodeficiency virus (HIV) or infectious hepatitis, type A,
             B or C

          -  Presence of any gastrointestinal condition or concomitant medication use (e.g.
             coumadin) that would render a patient at high risk for gastrointestinal bleeding as
             judged by treating physician

          -  History of any upper or lower gastrointestinal bleeding in the 6 months prior to
             enrollment

          -  Elevated international normalized ratio (INR) or Partial thromboplastin time (PTT)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srdan Verstovsek, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>M.D. Anderson's website</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2007</study_first_posted>
  <results_first_submitted>April 7, 2011</results_first_submitted>
  <results_first_submitted_qc>April 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2011</results_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CEP-701</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Myelofibrosis</keyword>
  <keyword>MF</keyword>
  <keyword>JAK2</keyword>
  <keyword>Tyrosine Kinase Inhibitor</keyword>
  <keyword>Lestaurtinib</keyword>
  <keyword>Chronic Idiopathic Myelofibrosis</keyword>
  <keyword>CIMF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 6/28/2007 through 10/25/2007. All participants recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 27 participants registered, 5 participants were ineligible to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CEP-701</title>
          <description>80 mg orally twice daily for 30 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CEP-701</title>
          <description>80 mg orally twice daily for 30 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="38" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Objective Response</title>
        <description>Objective response = Complete Response, absence sign/symptoms of disease (without use of growth factors, hydroxyurea, anagrelide, or transfusions for &gt; 1 month); Partial Response, absence of progressive disease (PD), and improvement in 2+ parameters (if abnormal): Absolute neutrophil count (ANC), hemoglobin, platelets, transfusions, splenomegaly, or bone marrow blasts; Clinical Improvement, absence of PD, and improvement in 1 parameter: ANC, hemoglobin, platelets, transfusions, splenomegaly, or bone marrow blasts). [International Working Group on Myelofibrosis Research and Treatment]</description>
        <time_frame>Response assessed after each 3 cycles (cycle = 30 days)</time_frame>
        <population>Intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>CEP-701</title>
            <description>80 mg orally twice daily for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Objective Response</title>
          <description>Objective response = Complete Response, absence sign/symptoms of disease (without use of growth factors, hydroxyurea, anagrelide, or transfusions for &gt; 1 month); Partial Response, absence of progressive disease (PD), and improvement in 2+ parameters (if abnormal): Absolute neutrophil count (ANC), hemoglobin, platelets, transfusions, splenomegaly, or bone marrow blasts; Clinical Improvement, absence of PD, and improvement in 1 parameter: ANC, hemoglobin, platelets, transfusions, splenomegaly, or bone marrow blasts). [International Working Group on Myelofibrosis Research and Treatment]</description>
          <population>Intention to treat.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Improvement (CI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years 10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CEP-701</title>
          <description>80 mg orally twice daily for 30 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Due to an accident</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <description>Due to a fall</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Debridement surgery with VAC placement</sub_title>
                <description>After an accidental fall</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Disease Progression</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Interstitial Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Elevated alanine aminotransferase</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Elevated alkaline phosphatase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Srdan Verstovsek M.D./Associate Professor</name_or_title>
      <organization>The University of Texas M. D. Anderson Cancer Center</organization>
      <phone>713-792-7305</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

